Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| IohexolNCT05580250 | Eli Lilly and CompanyPHASE1 | WITHDRAWN The sponsor made a business decision to withdraw the trial. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| LY3526318NCT05580250 | Eli Lilly and CompanyPHASE1 | WITHDRAWN The sponsor made a business decision to withdraw the trial. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| Hydroxychloroquine Sulfate + AzythromycinNCT04361461 | Apsen Farmaceutica S.A.PHASE3 | WITHDRAWN This study was canceled before enrollment due to a decision by the Sponsor | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| Hydroxychloroquine SulfateNCT04361461 | Apsen Farmaceutica S.A.PHASE3 | WITHDRAWN This study was canceled before enrollment due to a decision by the Sponsor | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| Buprenorphine SLNCT05339256 | New York State Psychiatric InstitutePHASE2 | WITHDRAWN Due to a federally mandated, institution-wide pause in research activities under the institution's Federal Wide Assurance (FWA) that occurred during the timeline for this study, recruitment was never initiated and no participants were enrolled. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| APSLXRNCT04674735 | Apsen Farmaceutica S.A.PHASE1 | WITHDRAWN Cancelled by Sponsor | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| NivolumabNCT06968988 | Washington University School of MedicinePHASE1 | SUSPENDED Protocol amendment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-04 |
| IpilimumabNCT06968988 | Washington University School of MedicinePHASE1 | SUSPENDED Protocol amendment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-04 |
| ZanzalintinibNCT06968988 | Washington University School of MedicinePHASE1 | SUSPENDED Protocol amendment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-04 |
| GemcitabineNCT06050252 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Other - evaluation of patients on first stage | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-04 |
| DurvalumabNCT06050252 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Other - evaluation of patients on first stage | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-04 |
| CisplatinNCT06050252 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Other - evaluation of patients on first stage | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-04 |
| AntihistamineNCT04612803 | University of CincinnatiPHASE3 | WITHDRAWN no funding for clinical research space | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-04 |
| DexamethasoneNCT06232044 | Alliance for Clinical Trials in OncologyPHASE1, PHASE2 | SUSPENDED Enrollment to Dose Level 1 cohort has been met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| Belantamab MafodotinNCT06232044 | Alliance for Clinical Trials in OncologyPHASE1, PHASE2 | SUSPENDED Enrollment to Dose Level 1 cohort has been met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| IberdomideNCT06232044 | Alliance for Clinical Trials in OncologyPHASE1, PHASE2 | SUSPENDED Enrollment to Dose Level 1 cohort has been met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| Glyceryl bromide/formoterol inhalation aerosolNCT07633314 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.PHASE2 | SUSPENDED The sponsor has decided to suspend study progress. Further implementation of the study is pending notification. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| TQC3927 inhalation aerosolNCT07633314 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.PHASE2 | SUSPENDED The sponsor has decided to suspend study progress. Further implementation of the study is pending notification. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| Room airNCT06327373 | Duke UniversityPHASE1, PHASE2 | WITHDRAWN Funding not obtained | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| OxygenNCT06327373 | Duke UniversityPHASE1, PHASE2 | WITHDRAWN Funding not obtained | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| TacrolimusNCT07349771 | Mayo ClinicPHASE2 | WITHDRAWN Sponsor declined to fund study due to inability to agree on IP. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| Mycophenolate MofetilNCT07349771 | Mayo ClinicPHASE2 | WITHDRAWN Sponsor declined to fund study due to inability to agree on IP. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| CyclophosphamideNCT07349771 | Mayo ClinicPHASE2 | WITHDRAWN Sponsor declined to fund study due to inability to agree on IP. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| AxatilimabNCT07349771 | Mayo ClinicPHASE2 | WITHDRAWN Sponsor declined to fund study due to inability to agree on IP. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-03 |
| Cemiplimab and FianlimabNCT07414992 | Memorial Sloan Kettering Cancer CenterPHASE2 | WITHDRAWN The sponsor is no longer supporting the trial because they are no longer interested in studying the drug in the target patient population. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-03 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |